Pioglitazone Tablets USP, 15 mg, 30 mg and 45 mg, had U.S. sales of approximately
Currently, Mylan has 166 ANDAs pending
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
This press release includes statements that constitute "forward-looking statements," including with regard to the launch of the products, marketing exclusivity, and expansion expectations. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to delay or prevent product introductions; the impacts of competition; changes in economic and financial conditions affecting the Company's business; uncertainties and matters beyond the control of management; and the
other risks detailed in the Company's periodic filings with the
(1) Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets and Pioglitazone Hydrochloride Tablets can cause or exacerbate congestive heart failure in some patients and therefore patients should be monitored for signs and symptoms of heart failure. Patients with symptomatic heart failure should not take this medication. Lactic acidosis can also occur as a result of Metformin accumulation. Patients that experience malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress should seek medical attention.
News Provided by Acquire Media